UNCONTROLLED WHEN PRINTED

Introduction

An anticholinergic bronchodilator. It inhibits the vagal reflexes that mediate bronchospasm.

Combined with a nebulised beta-2agonist (Salbutamol), Ipratropium bromide produces significantly greater bronchodilation than a beta-2 agonist alone.

Uses within SJA

For severe bronchospasm in severe to life-threatening asthma and COPD

Pharmacokinetics

Onset

Treatment between 5-15 minutes

Absorption

Inhalation (local): Minimal

Nasal Rapid and minimal

Metabolism

Hydrolysis partially; minimal absorption from GI tract, lungs Excretion: Primarily eliminated renally via active secretion

Pharmacodynamics

Desired Effects

Antagonizes acetylcholine receptors, producing bronchospasm

Side Effects

  • Headache
  • Nausea
  • Dry Mouth
  • Skin rash

Duration of Action

Half-life of 2-4 hours

Other Drug Interactions

Anticholinergic adverse effects


Page contributors:

DefaultDefault Author
St John WA
Want to help improve this article? Visit our Contribute page.

St John Ambulance Western Australia Ltd © Copyright 2020, All Rights Reserved

Privacy Policy | Copyright Statement & Disclaimer